KR102105111B1 - Energy drink composition containing increased biological active materials and preparation method thereof - Google Patents
Energy drink composition containing increased biological active materials and preparation method thereof Download PDFInfo
- Publication number
- KR102105111B1 KR102105111B1 KR1020180142305A KR20180142305A KR102105111B1 KR 102105111 B1 KR102105111 B1 KR 102105111B1 KR 1020180142305 A KR1020180142305 A KR 1020180142305A KR 20180142305 A KR20180142305 A KR 20180142305A KR 102105111 B1 KR102105111 B1 KR 102105111B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- energy drink
- drink composition
- active
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 235000015897 energy drink Nutrition 0.000 title claims abstract description 59
- 230000001965 increasing effect Effects 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 5
- 239000011149 active material Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 56
- 239000000284 extract Substances 0.000 claims description 36
- 229960003080 taurine Drugs 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 235000000346 sugar Nutrition 0.000 claims description 27
- 230000002292 Radical scavenging effect Effects 0.000 claims description 24
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 19
- 235000008434 ginseng Nutrition 0.000 claims description 19
- 235000020710 ginseng extract Nutrition 0.000 claims description 16
- 229940094952 green tea extract Drugs 0.000 claims description 16
- 235000020688 green tea extract Nutrition 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 235000009569 green tea Nutrition 0.000 claims description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 4
- 235000012734 epicatechin Nutrition 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000005554 pickling Methods 0.000 claims description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 6
- 238000001035 drying Methods 0.000 claims 1
- -1 flavonol compound Chemical class 0.000 abstract description 32
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 abstract description 14
- 235000011957 flavonols Nutrition 0.000 abstract description 14
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 11
- 238000011084 recovery Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 7
- 230000036542 oxidative stress Effects 0.000 abstract description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 5
- 230000008029 eradication Effects 0.000 abstract 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 25
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 17
- 229960001948 caffeine Drugs 0.000 description 17
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 240000004371 Panax ginseng Species 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000013824 polyphenols Nutrition 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000010025 steaming Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 244000228451 Stevia rebaudiana Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- 240000003444 Paullinia cupana Species 0.000 description 4
- 235000000556 Paullinia cupana Nutrition 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 2
- LJJZKMDEQVYRJX-UHFFFAOYSA-N 4,5,6-tripyridin-2-yltriazine Chemical compound N1=CC=CC=C1C1=NN=NC(C=2N=CC=CC=2)=C1C1=CC=CC=N1 LJJZKMDEQVYRJX-UHFFFAOYSA-N 0.000 description 2
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000220324 Pyrus Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940071264 lithium citrate Drugs 0.000 description 2
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000021017 pears Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- YTMFRMLVZQOBDR-UHFFFAOYSA-N 2-phenyl-3,4-dihydro-2h-chromen-4-ol Chemical class O1C2=CC=CC=C2C(O)CC1C1=CC=CC=C1 YTMFRMLVZQOBDR-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 229940085890 caffeine 30 mg Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/33—High-energy foods and drinks, sports drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 생리활성성분이 강화된 에너지 음료 조성물 및 이의 제조방법에 관한 것으로, 더 상세하게는 여주 추출액, 활성산양삼 추출액, 오미자당 추출액 및 녹차 추출액을 포함하여 플라보놀 화합물, 페놀릭산 화합물, 가바 등의 생리활성성분의 함량이 증진되어 항산화 활성 및 항당뇨 활성의 기능성이 강화된 에너지 음료 조성물 및 그 제조방법에 관한 것이다.The present invention relates to an energy drink composition with enhanced bioactive ingredients and a method for manufacturing the same, more specifically, a flavonol compound, a phenolic acid compound, a gaba, etc., including a Yeoju extract, an active ginseng extract, an Omija sugar extract, and a green tea extract It relates to an energy drink composition and a method of manufacturing the enhanced functionality of the antioxidant activity and anti-diabetic activity by increasing the content of the bioactive component of
에너지 음료는 에너지를 보충해주기 위한 음료수로서, 스포츠 드링크류가 주로 수분과 전해질을 보충해주는 목적으로 마신다면, 에너지 음료는 주로 에너지를 증가시킬 수 있는 성분이 들어있는 음료를 말하다. 특히 익스트림 스포츠를 즐기는 소비자나 고도의 신체활동 및 두뇌활동을 하는 젊은층에게 인기가 높다. 에너지 음료에는 신체의 신진대사를 촉진하여 활력을 주는 용도로 높은 열량을 가진 단순당과 카페인을 함유하는 과라나 추출물을 첨가하는 경우가 많고, 피로 회복이나 근 손상 방지 등을 위해 타우린 등의 아미노산과 비타민을 첨가하기도 한다. Energy drinks are drinks for replenishing energy, and if sports drinks are mainly used for the purpose of replenishing moisture and electrolytes, energy drinks are mainly drinks containing ingredients that can increase energy. It is especially popular with consumers who enjoy extreme sports or young people with high physical and brain activities. Energy drinks are often added with guarana extracts containing simple sugars and caffeine with high calories for the purpose of boosting the body's metabolism and revitalizing them, and amino acids and vitamins such as taurine for fatigue recovery and prevention of muscle damage Is also added.
과라나(guarana; Paullinia cupana)는 브라질 분지 원산의 무환자나무과 폴리니아속의 덩굴식물이다. 특히 과라나씨는 매우 고농도의 카페인이 함유되어 있어 식이 보충제로서 효과적인 자극제로 알려져 있다. 과라나의 카페인은 커피콩과 비교하여 약 2배 이상 많은 양을 함유되어 있어서 과라나 추출물은 에너지 음료의 첨가제 또는 각성제로 많이 사용되고 있다 (공개특허 10-2018-0059095).The guarana ( Paullinia cupana ) is a vine plant of the genus Aptaceae, native to the Brazilian basin. In particular, Guarana seeds are known to be effective stimulants as dietary supplements because they contain very high concentrations of caffeine. Guarana's caffeine contains about twice as much as coffee beans, so the guarana extract is often used as an additive or stimulant in energy drinks (Patent Publication 10-2018-0059095).
타우린은 1827년 황소의 담즙에서 처음 분리되었으며 타우린의 명칭은 황소를 의미하는 라틴어의 '타우르스'에서 유래된 아미노산의 일종이다. 타우린은 식물에서는 거의 함유되어 있지 않으나 인간의 주요 장기에는 다량 함유되어 있다. 타우린의 생리활성으로는 뇌의 교감신경에 대해 억제작용을 나타내고 저밀도 지단백질(LDL) 콜레스테롤 생성 억제를 통해 각종 혈관계 질환 예방에도 효과가 있음이 밝혀져 있다. 특히 타우린 생합성 과정에서 필수 요소인 시스테인 술피네이트 디카르복실라제(cysteine sulfinate decarboxylase) 활성이 쥐나 개에 비하여 인간이나 원숭이 등은 매우 낮아 이들 동물에 있어서 타우린의 생합성은 극히 제한적이다. 타우린은 운동 능력을 향상시키고 불안 증세를 완화시킬 수 있는 기능성을 가져서 에너지 음료를 구성하는 성분으로 사용되어 왔다. Taurine was first isolated from the bull's bile in 1827, and the name of the taurine is a type of amino acid derived from the Latin 'taurus', meaning bull. Taurine is rarely found in plants, but in major human organs. It has been found that the physiological activity of taurine has an inhibitory effect on the sympathetic nerves of the brain, and is also effective in preventing various vascular diseases by suppressing low-density lipoprotein (LDL) cholesterol production. In particular, taurine biosynthesis is extremely limited in these animals because the cysteine sulfinate decarboxylase activity, which is an essential element in the taurine biosynthesis process, is very low in humans and monkeys compared to rats and dogs. Taurine has been used as an ingredient in energy drinks because it has the ability to improve athletic performance and relieve anxiety.
산화적 스트레스(Oxidative stress)는 활성산소 생산계 및 소거계의 균형에 의해 거의 일정하게 유지되고 있던 생체 산화수준이 약제, 방사선, 허혈, 노화 등 여러 가지 요인에 의해 이러한 균형이 무너진 상태를 가리키는 것으로, 과도한 자유 라디칼을 발생시켜 인체의 항산화 기전의 균형을 깨트리고, 산화적 스트레스 결과 세포상해(특히 세포막 지질과 산화), DNA염기 수식에 의한 돌연변이, 세포사(apotosis) 유도 등을 일으켜서 동맥경화증, 퇴행성 뇌질환, 중풍, 파킨슨병, 헌팅턴병, 당뇨, 암, 알쯔하이머, 치매, 노화 등의 다양한 질환의 원인이 되고 있다. 이와 같은 산화적 스트레스는 발생된 라디칼의 소거에 의해 완화될 수 있다. Oxidative stress refers to a state in which the balance of the bio-oxidation, which was maintained almost constant by the balance of the free radical production system and the scavenging system, is broken by various factors such as drugs, radiation, ischemia, and aging. Atherosclerosis, degenerative disease by generating excessive free radicals, breaking the balance of the antioxidant mechanism of the human body, resulting in cellular injury (especially cell membrane lipids and oxidation), mutation by DNA base modification, and induction of cell death (apotosis) Brain diseases, paralysis, Parkinson's disease, Huntington's disease, diabetes, cancer, Alzheimer's, dementia, aging, etc. are causing various diseases. This oxidative stress can be alleviated by the elimination of generated radicals.
알파-글루코시다아제(glucosidase)는 소장점막에 존재하는 효소로서 식품 섭취 시에 탄수화물을 포도당 단위의 단당류로 분해하기 때문에 소화 및 흡수에 필수적이다. 이들 효소의 저해는 탄수화물 분해를 저해하게 하여 결과적으로 포도당 흡수 억제와 혈당상승을 감소시킬 수 있어서, 이들 효소의 저해활성을 갖는 제제는 당뇨 치료제로 사용되고 있다.Alpha-glucosidase (glucosidase) is an enzyme present in the mucous membrane of the small intestine and is essential for digestion and absorption because it breaks down carbohydrates into monosaccharides of glucose units when food is consumed. Inhibition of these enzymes can inhibit the degradation of carbohydrates, resulting in inhibition of glucose uptake and reduction of blood glucose, and thus agents having inhibitory activity of these enzymes are used as therapeutic agents for diabetes.
종래의 에너지 음료들은 카페인과 정제된 아미노산에 기초하여 신속한 에너지 공급에 맞춰져 있어서 산화적 스트레스로 발생된 라디칼 소거를 통한 원천적인 피로회복의 기능이 결여되어 있는 문제점이 있다. Conventional energy drinks are tailored to rapid energy supply based on caffeine and purified amino acids, and thus have a problem of lacking a function of original fatigue recovery through radical scavenging caused by oxidative stress.
본 발명의 목적은 여주 추출액, 활성산양삼 추출액, 오미자당 추출액 및 녹차 추출액을 포함하여 플라보놀 화합물, 페놀릭산 화합물 및 가바(GABA; γ-aminobutyric acid)의 함량이 증진되어 항산화 활성 및 항당뇨 활성의 기능성이 강화된 에너지 음료 조성물을 제공하는 것이다. The object of the present invention is to increase the content of flavonol compounds, phenolic acid compounds and GABA (γ-aminobutyric acid), including Yeoju extract, active ginseng extract, omija sugar extract, and green tea extract, thereby improving antioxidant activity and anti-diabetic activity. It is to provide an energy drink composition with enhanced functionality.
본 발명의 또 다른 목적은 플라보놀 화합물, 페놀릭산 화합물 및 가바의 함량이 증진되어 항산화 활성 및 항당뇨 활성의 기능성이 강화된 에너지 음료 조성물의 제조방법을 제공하는 것이다. Another object of the present invention is to provide a method for preparing an energy drink composition having enhanced functionality of antioxidant activity and anti-diabetic activity by increasing the content of flavonol compound, phenolic acid compound, and gaba.
상기 목적을 달성하기 위해, 본 발명은 여주 추출액, 활성산양삼 추출액, 오미자당 추출액, 녹차 추출액, 과라나 추출물, 타우린 및 물을 포함하는 에너지 음료 조성물을 제공한다. In order to achieve the above object, the present invention provides an energy drink composition comprising a Yeoju extract, an active ginseng extract, an Omija sugar extract, a green tea extract, a guarana extract, taurine and water.
여주 추출액Yeoju extract
본 발명의 에너지 음료 조성물은 여주 추출액을 유효성분으로 포함한다. The energy drink composition of the present invention contains the Yeoju extract as an active ingredient.
여주(Momordica charantia L.)는 알싸한 쓴맛을 내는 것을 특징으로 하는 과실로 이 쓴맛에는 식물스테롤 배당체들과 시트룰린과 같은 각종 아미노산, 갈락트론산, 펙틴, 카란틴 등의 생리활성성분이 다량 포함되어 있다. 그러나 여주는 쓴맛이 강하여 음료의 소재로 활용되는데 한계가 있으며 또한 에너지 음료에 이용된 바는 없다.Yeoju ( Momordica charantia L.) is a fruit characterized by a moderate bitter taste, which contains a large amount of phytosterol glycosides and various amino acids such as citrulline, galactonic acid, pectin, and caranthin. . However, Yeoju has a strong bitter taste, so there is a limit to using it as a material for drinks, and it has never been used for energy drinks.
여주 추출액은 여주를 덖음하여 제조한 여주분말을 10~20 배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 1 브릭스 농도로 추출하여 제조한다. The Yeoju extract is prepared by extracting the Yeoju powder produced by diluting Yeoju with 10-20 times water, extracting it at 120 ° C for 8 hours, filtering it, and extracting it at a concentration of 1 Brix.
본 발명의 에너지 음료 조성물에서 여주 추출액을 45~55 중량%로 포함하는데, 45 중량% 미만이면 여주 유래의 생리활성성분이 충분치 않고 55 중량% 초과이면 여주의 쓴맛에 의한 기호성이 좋이 않을 수 있다.In the energy drink composition of the present invention, the extract of Yeoju is contained in 45 to 55% by weight, and if it is less than 45% by weight, the physiologically active ingredient derived from Yeoju is not sufficient and if it exceeds 55% by weight, palatability due to bitterness of the bitter may not be good. .
활성산양삼Active Mountain Ginseng 추출액 Extract
본 발명의 에너지 음료 조성물은 활성산양삼 추출액을 유효성분으로 포함한다. The energy drink composition of the present invention includes an active wild ginseng extract as an active ingredient.
본 발명에서 산양삼은 산간의 삼림하에서 인위적으로 종자나 묘삼을 파종 및 이식하여 재배한 삼을 의미한다. 산양삼은 효능 면에서는 재배 인삼보다 효과가 더욱 좋은 것으로 알려져 있으며, 한의학에서는 산양삼을 자연 산삼 다음으로 효능을 높고, 재배 인삼과 비교하였을 시 인삼 사포닌 형태의 진세노사이드 함량이 높다고 보고되어 있다.In the present invention, mountain ginseng means hemp grown artificially by sowing and transplanting seeds or seedlings under a mountain forest. Goyangsam is known to be more effective than cultivated ginseng in terms of efficacy, and oriental medicine reports that ginseng ginseng has the highest efficacy after natural ginseng, and has higher ginsenoside content in the form of ginseng saponin when compared to cultivated ginseng.
본 발명에서 ‘활성산양삼’은 증숙과 고온숙성을 3회 반복하여 제조되는 것으로 생리활성성분의 함량이 증진되도록 산양삼을 가공한 것을 말한다. In the present invention, 'active goat ginseng' is produced by repeating steaming and high-temperature aging three times, and refers to processing of wild ginseng so that the content of physiologically active ingredients is enhanced.
본 발명에서 '증숙'은 100℃에서 30~60분간 수증기로 찌는 것을 의미한다. 증숙시간이 30분 미만인 경우 충분한 증숙이 진행되지 않아 숙성과 같은 후속 단계가 원활하지 않을 수 있고 잡균의 오염이 발생될 수 있으며, 60분 초과하여 증숙될 경우는 오랜 열처리로 산양삼의 생리활성성분이 파괴될 수 있다.In the present invention, 'steaming' means steaming with water vapor at 100 ° C for 30 to 60 minutes. If the steaming time is less than 30 minutes, sufficient steaming does not proceed, so that subsequent steps such as aging may not be smooth and contamination of germs may occur. Can be destroyed.
본 발명에서 '고온숙성'은 70~90℃에서 2∼4일간 유지하는 것을 의미한다. 숙성온도가 70℃ 미만이거나 숙성기간이 2일 미만인 경우 숙성이 원활히 이루어지지 않으며, 숙성온도가 90℃ 초과하거나 숙성기간이 4일 초과의 경우 생산된 생리활성물질이 분해되어 함량이 감소될 수 있다.In the present invention, 'high temperature ripening' means maintaining at 70 to 90 ° C for 2 to 4 days. When the aging temperature is less than 70 ℃ or the aging period is less than 2 days, aging is not smoothly performed. If the aging temperature exceeds 90 ℃ or the aging period exceeds 4 days, the produced bioactive substances may decompose and the content may be reduced. .
본 발명에서 '활성산양삼 추출액'은 상기와 같이 제조된 활성산양삼을 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화한 후, 활성산양삼 분말에 10∼20배(v/w) 가수하여 120℃에서 8∼10시간 동안 추출한 후 여과하여 고형분 함량이 4%(4 브릭스) 되도록 농축하여 제조될 수 있다.In the present invention, the 'active red ginseng extract' is dried for 2 to 3 days at 50 to 55 ° C, and then powdered to 100 mesh or less, and then 10 to 20 times (v / w) active red ginseng powder prepared as described above. ) It can be prepared by extracting at 120 ° C. for 8 to 10 hours by hydrolysis and then filtering to concentrate to a solid content of 4% (4 brix).
본 발명의 에너지 음료 조성물에서 활성산양삼 추출액을 1~5 중량%로 포함하는데, 1 중량% 미만이면 산양삼에 기인하는 생리활성을 기대하기 어렵고 5 중량% 초과이면 음료 제조시 비용 상승 문제가 발생할 수 있다.In the energy drink composition of the present invention, the active wild ginseng extract is included in 1 to 5% by weight, but if it is less than 1% by weight, it is difficult to expect the physiological activity caused by the wild ginseng, and if it exceeds 5% by weight, a problem of cost increase may occur during beverage production. .
오미자당Omija sugar 추출액 Extract
본 발명의 에너지 음료 조성물은 오미자당 추출액을 유효성분으로 포함한다.The energy drink composition of the present invention contains the extract of Schisandra chinensis as an active ingredient.
오미자(chizandra chinensis BAALL)는 단맛, 짠맛, 신맛, 쓴맛, 매운맛의 5가지 맛을 느낄 수 있어 오미자라고 불리며 그 중 신맛이 가장 강하다. 오미자는 시잔드린(schizandrin), 시잔드란(schiazndran), 고미신(gomisin) 등의 리그난 형태의 화합물과 색소 등의 약리적 작용을 하는 성분들을 함유하고 있어서 천식치료에 효능이 탁월하고 눈을 밝게 해주고, 알코올 해독, 콜레스테롤 저하, 고지혈증 완화, 항암과 항종양 등 다양하게 생리적 활성을 갖는다. Omija (chizandra chinensis BAALL) is called omija because it has five flavors: sweet, salty, sour, bitter, and spicy. Omija contains lignan-type compounds such as schizandrin, schizndran, and gomisin, and pharmacological components such as pigments, so it has excellent efficacy in treating asthma and brightens eyes, It has various physiological activities such as detoxifying alcohol, lowering cholesterol, alleviating hyperlipidemia, anti-cancer and anti-tumor.
본 발명에서 '오미자당 추출액'은 오미자와 설탕을 1 : 1 중량비로 혼합하여 50~60일 동안 당절임 후 액만 여과하여 60 브릭스 농도로 제조한다.In the present invention, 'Omija sugar extract' is prepared by mixing Omizawa sugar in a 1: 1 weight ratio, pickling for 50 to 60 days, and filtering only the liquid to obtain a concentration of 60 Brix.
본 발명의 에너지 음료 조성물에서 오미자당 추출액을 4~12 중량%로 포함하는데, 4 중량% 미만이면 당 함유가 적어 에너지 음료로서 효과를 충분히 낼 수 없고 12 중량% 초과이면 단맛이 너무 강해 기호성에 문제가 발생할 수 있다.In the energy drink composition of the present invention, the extract of Schisandra chinensis is contained in 4 to 12% by weight, but if it is less than 4% by weight, the content of sugar is low, and thus the effect cannot be sufficiently achieved as an energy drink. Can occur.
녹차 추출액Green Tea Extract
본 발명의 에너지 음료 조성물은 녹차 추출액을 유효성분으로 포함한다. The energy drink composition of the present invention contains green tea extract as an active ingredient.
녹차 추출액은 녹차분말을 10~20배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 2 브릭스 농도로 추출하여 제조한다.The green tea extract is prepared by extracting green tea powder at a water concentration of 10 to 20 times, extracting it at 120 ° C. for 8 hours, and extracting it at a concentration of 2 Briggs.
본 발명의 에너지 음료 조성물에서 녹차 추출액을 1~5 중량%로 포함하는데, 1 중량% 미만이면 카페인과 더불어 생리활성물질의 함량이 충분하지 않으며 5 중량% 초과이면 녹차의 떫은맛에 의해 기호성 문제가 발생할 수 있다.In the energy drink composition of the present invention, the green tea extract is contained in 1 to 5% by weight, and if it is less than 1% by weight, the content of physiologically active substances is not sufficient in addition to caffeine, and if it exceeds 5% by weight, palatability may occur due to the astringent taste of green tea. You can.
과라나 추출물Guarana extract
본 발명의 에너지 음료 조성물은 과라나 추출물을 0.8~1.4 중량%로 포함한다. The energy drink composition of the present invention comprises a guarana extract at 0.8 to 1.4% by weight.
본 발명에서 과라나 추출물은 분말상 또는 액상의 추출물로 사용될 수 있으며, 상업적으로 용이하게 입수할 수 있다. Guarana extract in the present invention can be used as a powder or liquid extract, it can be easily obtained commercially.
본 발명의 에너지 음료 조성물에서 과라나 추출물을 0.8 중량% 미만이면 에너지 음료의 주성분인 카페인 함량이 적고 1.4 중량% 초과이면 카페인 함량이 과다하여 카페인 부작용이 발생할 수 있다.In the energy drink composition of the present invention, if the guarana extract is less than 0.8% by weight, caffeine content, which is the main component of the energy drink, is low, and if it is more than 1.4% by weight, caffeine content is excessive, which may cause caffeine side effects.
타우린Taurine
본 발명의 에너지 음료 조성물은 타우린을 0.2~2.0 중량%로 포함한다. The energy drink composition of the present invention contains taurine in 0.2 to 2.0% by weight.
타우린은 상업적으로 용이하게 입수할 수 있다. Taurine is readily available commercially.
본 발명의 에너지 음료 조성물에서 타우린을 0.2 중량% 미만이면 음료의 주성분인 타우린 함량이 충분치 않고, 2.0 중량% 초과이면 타우린 과다에 따른 기호성과 부작용이 따를 수 있다.If the taurine in the energy drink composition of the present invention is less than 0.2% by weight, the main ingredient of the beverage is not sufficient, and if it is more than 2.0% by weight, palatability and side effects may be caused by excessive taurine.
필요에 따라서, 본 발명의 에너지 음료 조성물은 비타민, 감미료 (스테비아, 아스파탐 등), 과일농축액(사과, 블루베리, 배, 딸기, 포도, 복숭아 등), 한약재 추출물 등의 첨가제를 추가로 포함할 수 있다. If necessary, the energy drink composition of the present invention may further include additives such as vitamins, sweeteners (stevia, aspartame, etc.), fruit concentrates (apples, blueberries, pears, strawberries, grapes, peaches, etc.), herbal medicine extracts, etc. have.
본 발명에 따른 에너지 음료 조성물은 카페인 2~3 mg/100ml, 타우린 186 mg/100ml 이상, 환원당 26 ~ 60 mg/ml를 함유하여 신속한 에너지 공급, 각성 및 운동력 회복 효과를 가지며, 아울러 플리보놀 화합물 329 ㎍/ml 이상, 페놀릭산 화합물 72 ㎍/ml 이상, 및 가바 1 mg/100ml 이상 함유하여 증진된 항산화 활성을 가져서 산화적 스트레스로 발생된 라디칼 소거를 통한 원천적인 피로회복의 기능을 가지며, 또한 증진된 항당뇨 활성을 갖는다 (표 2~표 4, 도 3).The energy drink composition according to the present invention contains caffeine 2-3 mg / 100ml, taurine 186 mg / 100ml or more, and reducing sugar 26 to 60 mg / ml, thereby providing rapid energy supply, awakening and exercise recovery, and also a flavonol compound 329 Contains ㎍ / ml or more, 72 µg / ml or more of phenolic acid compounds, and 1 mg / 100 ml or more of gaba, so it has enhanced antioxidant activity and has the function of fundamental fatigue recovery through radical scavenging caused by oxidative stress. Has anti-diabetic activity (Table 2 ~ Table 4, Figure 3).
또한 본 발명의 에너지 음료 조성물은 유효성분들의 맛, 향이 서로 잘 조화되어 기호성 또한 우수하다.In addition, the energy drink composition of the present invention is excellent in palatability because the taste and aroma of the active ingredients are well harmonized with each other.
본 발명의 또 다른 목적에 따라서, 본 발명은 According to another object of the present invention, the present invention
ⅰ) 여주분말에 10~20 배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 1 브릭스 농도의 여주 추출액을 제조하는 단계; Iv) preparing a Yeoju extract with a concentration of 1 Brix by adding 10 ~ 20 times water to the Yeoju powder and extracting it for 8 hours at 120 ℃;
ⅱ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 활성산양삼을 제조한 후, 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 120℃에서 8∼10시간 동안 추출한 후 여과하여 4 브릭스 농도의 활성산양삼 추출액을 제조하는 단계; Ii) Steamed wild ginseng at 100 ℃ for 30 ~ 60 minutes, and steamed wild ginseng was repeated three times for 2-4 days at 70-90 ℃ to prepare active ginseng, and then dried at 50-55 ℃ for 2-3 days After making the powder to 100 mesh or less, and 10 to 20 times (v / w) hydrolyzed to extract for 8 to 10 hours at 120 ℃ filtered to prepare an active wild ginseng extract of 4 Brix concentration;
ⅲ) 오미자와 설탕을 1 : 1 중량비로 혼합하여 50~60일 동안 당절임 후 액만 여과하여 60 브릭스 농도의 오미자당 추출액을 제조하는 단계; Iv) preparing Omija sugar extract of 60 Brix concentration by mixing Omizawa sugar in a 1: 1 weight ratio and pickling the sugar for 50-60 days and filtering only the liquid;
ⅳ) 녹차분말을 10~20배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 2 브릭스 농도의 녹차 추출액을 제조하는 단계; Iv) preparing a green tea extract having a concentration of 2 Brix by filtering the green tea powder with
ⅴ) 여주 추출액 45~55 중량%, 활성산양삼 추출액 1~5 중량%, 오미자당 추출액 4~12 중량%, 녹차 추출액 1~5 중량%, 과라나 추출물 0.8~1.4 중량%, 타우린 0.2~0.3 중량% 및 나머지 물을 혼합하는 단계를 포함하여 이루어지는 에너지 음료 조성물의 제조방법을 제공한다. Ⅴ) Yeoju extract 45 ~ 55% by weight, Active wild ginseng extract 1 ~ 5% by weight, Omija sugar extract 4 ~ 12% by weight, Green tea extract 1 ~ 5% by weight, Guarana extract 0.8 ~ 1.4% by weight, Taurine 0.2 ~ 0.3% by weight And mixing the rest of the water.
필요에 따라서, 본 발명의 에너지 음료 조성물의 제조방법은 단계 v)에서 비타민, 감미료 (스테비아, 아스파탐 등), 과일농축액(사과, 블루베리, 배, 딸기, 포도, 복숭아 등), 한약재 추출물 등의 첨가제를 추가로 포함하여 혼합할 수 있다. If necessary, the method for preparing the energy drink composition of the present invention includes vitamins, sweeteners (stevia, aspartame, etc.), fruit concentrates (apples, blueberries, pears, strawberries, grapes, peaches, etc.), herbal extracts, etc. Additives may be further included to mix.
본 발명의 제조방법에 의해 제조된 에너지 음료 조성물은 플라보놀 화합물, 페놀릭산 화합물 및 가바의 함량이 증진되어 항산화 활성 및 항당뇨 활성의 기능성이 강화된다. The energy drink composition prepared by the production method of the present invention has enhanced flavonol compounds, phenolic acid compounds and gaba contents, thereby enhancing the functionality of antioxidant activity and anti-diabetic activity.
본 발명에 따른 에너지 음료 조성물은 환원당, 타우린, 카페인을 함유하여 신속한 에너지 공급, 각성 및 운동력 회복 효과를 가지며, 아울러 플리보놀 화합물, 페놀릭산 화합물 및 가바 등의 생리활성성분이 현저히 증진되어 항산화 활성을 가져서 산화적 스트레스로 발생된 라디칼 소거를 통한 원천적인 피로회복의 기능을 가지며, 또한 증진된 항당뇨 활성을 갖는다. The energy drink composition according to the present invention contains reducing sugar, taurine, and caffeine to have a rapid energy supply, wakefulness, and exercise recovery effect, and also improves antioxidant activity by remarkably enhancing the physiologically active ingredients such as the flavonol compound, phenolic acid compound, and gaba As a result, it has a function of original fatigue recovery through radical scavenging caused by oxidative stress, and also has enhanced anti-diabetic activity.
이와 같은 강화된 활성으로 인하여 본 발명의 에너지 음료 조성물은 우수한 각성제 효과로 인해 운동력 회복과 졸음개선 또는 주의력결핍, 과잉행동장애, 기면증 개선에 유용하며, 항산화 활성과 항당뇨 효능이 강화되어 피로회복용 건강기능성 음료이다.Due to this enhanced activity, the energy drink composition of the present invention is useful for restoring motor power and improving drowsiness or attention deficit, hyperactivity disorder, narcolepsy due to the excellent stimulant effect, and has enhanced antioxidant activity and anti-diabetic effect, thereby improving fatigue recovery health It is a functional beverage.
또한 본 발명의 에너지 음료 조성물은 유효성분들의 맛, 향이 서로 잘 조화되어 기호성 또한 우수하다.In addition, the energy drink composition of the present invention is excellent in palatability because the taste and aroma of the active ingredients are well harmonized with each other.
도 1은 본 발명에 따라 제조된 에너지 음료 조성물의 사진이다.
도 2는 본 발명의 에너지 음료 조성물의 총 페놀릭스 및 총 플라보노이드스 함량을 나타낸 그래프이다. 도 2a는 총 페놀릭스 함량을 나타낸 것이며, 도 2b는 총 플라보노이드스 함량을 나타낸 것이다.
도 3은 본 발명의 에너지 음료 조성물의 항산화 활성을 나타낸 그래프이다. 도 3a는 DPPH 라디칼 소거활성을 나타낸 것이며, 도 3b는 ABTS 라디칼 소거활성을 나타낸 것이며, 도 3c는 히드록실 라디칼 소거활성을 나타낸 것이며, 도 3d는 FRAP 환원력을 나타낸 것이다.
도 4는 본 발명의 에너지 음료 조성물의 알파-글루코시다아제 저해활성 나타낸 그래프이다. 1 is a photograph of an energy drink composition prepared according to the present invention.
2 is a graph showing the total phenolics and total flavonoids content of the energy drink composition of the present invention. Figure 2a shows the total phenolics content, Figure 2b shows the total flavonoids content.
3 is a graph showing the antioxidant activity of the energy drink composition of the present invention. FIG. 3A shows DPPH radical scavenging activity, FIG. 3B shows ABTS radical scavenging activity, FIG. 3C shows hydroxyl radical scavenging activity, and FIG. 3D shows FRAP reducing power.
4 is a graph showing the alpha-glucosidase inhibitory activity of the energy drink composition of the present invention.
다음의 실시예들에 의해 본 발명이 더 상세히 설명된다. 이들 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들에 의해 제한되어서는 안된다.The invention is explained in more detail by the following examples. These examples are intended to illustrate the invention, and the scope of the invention should not be limited by them.
제조예Manufacturing example 1. 에너지 음료 조성물 제조 1. Preparation of energy drink composition
<여주 추출액 제조><Preparation of Yeoju extract>
추출용기에 건조 여주분말 50 g과 정제수 0.5 L를 넣은 후 120℃에서 8시간 추출하여 거름망으로 걸러내어 여주 추출물(1 브릭스)을 제조하였다.50 g of dried Yeoju powder and 0.5 L of purified water were added to the extraction container, and then extracted at 120 ° C. for 8 hours, filtered through a strainer to prepare a Yeoju extract (1 Brix).
<활성산양삼 추출액 제조> <Preparation of active wild ginseng extract>
3년근 이상 산양삼 1 kg을 흐르는 물에 3회 세척하고 완전히 물기를 제거한 후, 증자기에서 100℃, 1시간 증숙한 후 건조 채반에 담고 수분이 증발되게 하면서 75℃에서 3일간 숙성시키는 과정(증숙과 고온숙성)을 3회 진행하여 활성산양삼을 제조한 후 55℃에서 3일간 열풍 건조하고 분쇄기로 분쇄하여 분말화한 후, 분말 50 g을 추출용기에 넣고 10배의 정제수(0.5 L)를 첨가하고 120℃에서 8시간 추출하여 산양삼 추출물(4 브릭스)을 제조하였다. After washing 3 times in flowing water of 1 kg of wild ginseng for 3 years or more and completely draining the water, boil it at 100 ℃ for 1 hour in a steamer, put it on a dry plate and let it evaporate for 3 days at 75 ℃ (steaming) And high-temperature aging) 3 times to prepare active ginseng and then dry it with hot air at 55 ° C for 3 days, pulverize it with a grinder, powder 50 g into an extraction container and add 10 times purified water (0.5 L) And extracted at 120 ℃ for 8 hours to prepare a wild ginseng extract (4 brix).
<오미자당 추출액 제조><Omija sugar extract preparation>
오미자 500 g와 설탕 500 g을 혼합하여 60일 동안 당절임 한 후 액만 여과하여 오미자당 추출액을 제조하였다. 500 g of Omija and 500 g of sugar were mixed and pickled for 60 days, and then the liquid was filtered to prepare an Omija sugar extract.
<녹차 추출액 제조> <Production of green tea extract>
추출용기에 건조 녹차분말 50 g과 정제수 0.5 L를 넣은 후 120℃에서 8시간 추출하여 거름망으로 걸러내어 녹차 추출물(2 브릭스)을 제조하였다.50 g of dry green tea powder and 0.5 L of purified water were added to the extraction container, and then extracted at 120 ° C. for 8 hours, filtered through a strainer to prepare green tea extract (2 brix).
과라나 추출분말과 타우린, 첨가제인 스테비아, 비타민 C는 구입하여 사용하였다.Guarana extract powder, taurine, additives stevia and vitamin C were purchased and used.
상기와 같이 준비된 여주 추출액, 활성산양삼 추출액, 오미자당 추출액, 녹차 추출액, 과라나 추출물, 타우린, 첨가제 (스테비아, 비타민 C) 및 물을 하기 표 1과 같은 배합비율로 혼합하여 에너지 음료 조성물을 제조하였다 (실시예 1~4).An energy drink composition was prepared by mixing Yeoju extract, active ginseng extract, Omija sugar extract, green tea extract, Guarana extract, taurine, additives (Stevia, Vitamin C) and water prepared in the above manner at the mixing ratio shown in Table 1 below. Examples 1-4).
비교를 위하여, 여주 추출액만을 유효성분으로 함류하는 음료 조성물을 제조하였다(비교예) For comparison, a beverage composition containing only Yeoju extract as an active ingredient was prepared (Comparative Example)
(brix 60%) Omija sugar extract
(brix 60%)
(카페인 30 mg/g)Guarana Extract Powder
(Caffeine 30 mg / g)
시험예Test example 1. 이화학적 특성 분석 1. Analysis of physicochemical properties
상기에서 제조된 실시예들과 비교예의 음료 조성물의 이화학적 특성은 pH, 산도, 가용성 고형분과 환원당 함량을 측정하여 분석하였다. The physicochemical properties of the beverage compositions of Examples and Comparative Examples prepared above were analyzed by measuring pH, acidity, soluble solids and reducing sugar content.
pH는 pH 미터기를 사용하여 측정하였고 산도는 중화적정법을 통해 0.1 N NaOH 소비량에 따라 역적정하고 최종 젖산(%)으로 표기하였다. 가용성 고형분은 당도계를 이용하여 측정하였다. 환원당 함량은 DNS(dinitrosalicylic acid) 법에 따라서, 적절히 희석한 각각의 비교예와 실시예들의 조성물 1 ml에 DNS 시약 3 ml를 가하고 비등 냉각시켜 분광광도계를 사용하여 550 nm에서 흡광도를 측정하고 미리 작성해둔 표준품(포도당) 검량곡선에 대입하여 mg으로 산출하였고, 그 결과를 표 2에 나타냈다.The pH was measured using a pH meter, and the acidity was reverse titrated according to the consumption amount of 0.1 N NaOH through the neutralization titration method and expressed as the final lactic acid (%). Soluble solids were measured using a sugar meter. The reducing sugar content was measured according to the DNS (dinitrosalicylic acid) method, by adding 3 ml of a DNS reagent to 1 ml of the composition of each of the comparative examples and examples diluted appropriately, and boil-cool to measure the absorbance at 550 nm using a spectrophotometer and prepare in advance. It was calculated as mg by substituting the calibration curve for the standard product (glucose), and the results are shown in Table 2.
(Brix, %)Soluble solids
(Brix,%)
표 2에 나타낸 바와 같이, 실시예 1~4는 pH가 평균 3.74이며 산가 0.34 ~ 0.62로 에너지 음료로서 적합하여, 가용성 고형분이 5 ~ 8.7 브릭스 및 환원당 함량이 26.69 ~ 56.23 mg/ml로 신속한 에너지 공급에 적합하게 함유하고 있다. As shown in Table 2, Examples 1 to 4 have an average pH of 3.74 and an acid value of 0.34 to 0.62, which is suitable as an energy drink, so that the soluble solid content is 5 to 8.7 Brix and the reducing sugar content is 26.69 to 56.23 mg / ml, providing rapid energy. It is suitably contained in.
시험예Test example 2. 생리활성성분 분석 2. Analysis of bioactive components
상기에서 제조된 실시예들과 비교예의 음료 조성물의 타우린 및 카페인 함략을 측정하고, 가바, 플라보놀 화합물 및 페놀릭산 화합물의 생리활성성분의 함량을 분석하였다. The taurine and caffeine content of the beverage compositions of the examples and comparative examples prepared above were measured, and the contents of the bioactive components of the gaba, flavonol compound and phenolic acid compound were analyzed.
타우린과 가바 함량 분석은 자동 아미노산 분석기를 사용하여 분석하였고, 카페인, 플라보놀 화합물 및 페놀릭산 화합물의 함량 분석은 고성능 액체크로마토그래피(HPLC, high press liquid chromatograph)를 사용하여 수행하였다.Taurine and gaba content analysis was performed using an automatic amino acid analyzer, and content analysis of caffeine, flavonol compound, and phenolic acid compound was performed using high-performance liquid chromatography (HPLC).
<타우린 및 가바 분석><Analysis of Taurine and Gaba>
타우린과 가바 함량 분석을 위해, 각각의 실시예와 비교예의 조성물 1 ml를 시험관에 정확히 칭량하고 HPLC 등급 물 4 ml를 첨가하고 60℃에서 1시간 가수분해 과정을 수행하였다. 가수분해 후 5-술포살리실산(sulfosalicylic acid) 2 ml를 첨가하고 2시간 동안 단백질을 침전시키고 상등액만을 60℃에서 완전 증발시켰다. 완전 증발에 의해 남은 여액을 리튬 시트레이트 버퍼(pH 2.2) 2 ml를 첨가하여 용해시키고 5-술포살리실산 2 ml를 첨가하고 2시간 방치시켜 단백질을 침전시킨 뒤 약 3분간 원심분리한 뒤에 상등액만을 60℃의 감압조건하에 완전 증발시켰다. 이후 남은 여액에 대해 리튬 시트레이트 버퍼(pH 2.2) 2 ml를 첨가하여 용해하고 0.45 ㎛ 멤브레인 필터로 여과한 것을 자동 아미노산 분석기에 주입하여 일련의 방법을 토대로 분석을 수행하였고, 그 결과를 표 3에 나타냈다. For taurine and gaba content analysis, 1 ml of each example and comparative example composition was accurately weighed in a test tube, 4 ml of HPLC grade water was added, and a hydrolysis process was performed at 60 ° C for 1 hour. After hydrolysis, 2 ml of 5-sulfosalicylic acid was added, the protein was precipitated for 2 hours, and only the supernatant was completely evaporated at 60 ° C. After the complete evaporation, the remaining filtrate was dissolved by adding 2 ml of lithium citrate buffer (pH 2.2), and 2 ml of 5-sulfosalicylic acid was added and left to stand for 2 hours to precipitate the protein. It was evaporated completely under reduced pressure at ℃. Thereafter, 2 ml of lithium citrate buffer (pH 2.2) was added to the remaining filtrate to dissolve and filtered through a 0.45 μm membrane filter was injected into an automatic amino acid analyzer to perform analysis based on a series of methods. Showed.
2)nd: 검출되지 않음. 1) All experiments were performed three times and expressed as an average value.
2) nd: not detected.
<카페인, 플라보놀 화합물 및 페놀릭산 화합물 분석><Caffeine, flavonol compound and phenolic acid compound analysis>
각각의 실시예와 비교예의 조성물을 0.45 ㎛ 필터로 1차 여과한 것을 HPLC 분석 시료로 준비하였다. The first filtration of the compositions of each Example and Comparative Example with a 0.45 μm filter was prepared as an HPLC analysis sample.
분석에 사용된 칼럼은 X-BridgeTM C18(4.6×250 mm, 5 ㎛, Waters사, 미국)이며 분석 용매는 0.2% 수중 글라시알 아세트산 함유 물(이동상 A)과 0.2% 수중 글라시알 아세트산 함유 아세토나이트릴(이동상 B)로 준비하였고 용매의 조건은 이동상 B 기준으로 각각 10, 15, 20, 25, 30, 35, 40, 45, 55 및 60분 동안 15%, 5%, 15%, 5%, 10%, 50%, 50%, 60%, 80% 및 90%로 유지시켰다. 준비된 각각의 분석 시료 20 ㎕를 주입하였고 이동상의 속도는 30℃에서 1 ml/min로 유지하였고 카페인과 플라보놀 및 페놀릭산 화합물은 diode array UV 검출기의 흡광도 280 nm(페놀릭산 화합물 측정 파장)와 270 nm(카페인, 플라보놀 화합물 측정 파장)에서 측정하여 정량하였고, 그 결과를 표 3 및 표 4에 나타냈다. The column used for the analysis was X-Bridge TM C18 (4.6 × 250 mm, 5 μm, Waters, USA), and the analysis solvent was 0.2% water containing glacial acetic acid (mobile phase A) and 0.2% water containing glacial acetic acid aceto Prepared with nitrile (mobile phase B) and solvent conditions were 15%, 5%, 15%, 5% for 10, 15, 20, 25, 30, 35, 40, 45, 55 and 60 minutes, respectively, based on mobile phase B. , 10%, 50%, 50%, 60%, 80% and 90%. 20 µl of each prepared analytical sample was injected, and the speed of the mobile phase was maintained at 1 ml / min at 30 ° C. Caffeine, flavonol, and phenolic acid compounds absorbed 280 nm (wavelength measured by the phenolic acid compound) of the diode array UV detector and 270 It was quantified by measuring at nm (caffeine, flavonol compound measurement wavelength), and the results are shown in Tables 3 and 4.
2)nd: 검출되지 않음. 1) All experiments were performed three times and expressed as an average value.
2) nd: not detected.
표 3에 나타낸 바와 같이, 실시예 1~4의 에너지 음료 조성물은, 타우린이 188.12~192.33 mg/100ml의 함량으로 함유되고, 카페인이 2.02~2.95 mg/100ml의 함량으로 함유되어 에너지 음료로서 적합하다.As shown in Table 3, the energy drink composition of Examples 1 to 4, taurine is contained in an amount of 188.12 to 192.33 mg / 100ml, caffeine is contained in an amount of 2.02 to 2.95 mg / 100ml, and is suitable as an energy drink. .
본 발명에 따른 에너지 음료 조성물은 가바 함량이 비교예 (0.51 mg/100ml)에 비하여 2~16배 (1.03~8.22 mg/100ml) 증진되었음을 확인할 수 있다.Energy drink composition according to the present invention can be confirmed that the gaba content is 2-16 times (1.03 ~ 8.22 mg / 100ml) enhanced compared to the comparative example (0.51 mg / 100ml).
또한 표 4에 나타낸 바와 같이, 실시예 1~4의 에너지 음료 조성물은, 비교예의 음료 조성물에 비하여, 플라보놀 화합물(epigallocatechin, catechin, epicatechin, epigallocatechin gallate, rutin, catechin gallate, quercetin, naringin, naringenin, formonoetin)과 페놀릭산 화합물(gallic acid, protocatechuic acid, chlorgenic acid, p-hydrobenzoic acid, vanillic acid, veratric acid, t-cinnamic acid)의 함량이 유의하게 증진되었다. 특히 본 발명의 에너지 음료 조성물은 에피카테킨(epicatechin)을 16.85 ㎛/ml 이상, 클로로제닉산(chlorgenic acid)을 40.16 ㎛/ml 이상 함유하여 현저히 증진되었음을 확인할 수 있다. In addition, as shown in Table 4, the energy drink composition of Examples 1 to 4, compared to the beverage composition of the comparative example, flavonol compounds (epigallocatechin, catechin, epicatechin, epigallocatechin gallate, rutin, catechin gallate, quercetin, naringin, naringenin, formonoetin) and phenolic acid compounds (gallic acid, protocatechuic acid, chlorgenic acid, p-hydrobenzoic acid, vanillic acid, veratric acid, t-cinnamic acid). In particular, it can be confirmed that the energy drink composition of the present invention contains an epicatechin of 16.85 μm / ml or more and a chlorogenic acid of 40.16 μm / ml or more.
상기와 같은 결과로부터 본 발명의 에너지 음료 조성물은 생리활성성분이 현저히 강화됨을 알 수 있다.From the above results, it can be seen that the energy drink composition of the present invention has a significantly enhanced bioactive component.
시험예Test example 3. 수용성 3. Water soluble 페놀릭스Phenolic 및 And 플라보노이드스Flavonoids 함량 분석 Content analysis
상기에서 제조된 실시예들과 비교예의 음료 조성물의 총 페놀릭스 및 플라보노이드스 함량을 Folin-Denis 및 Davis법으로 비교 분석하였다.The total phenolics and flavonoids contents of the beverage compositions of Examples and Comparative Examples prepared above were compared and analyzed by Folin-Denis and Davis method.
<수용성 페놀릭스 함량><Water soluble phenolics content>
수용성 페놀릭스 함량은 Folin Denis법(1912)을 약간 변형하여 측정하였다.The water-soluble phenolics content was measured by slightly modifying the Folin Denis method (1912).
구체적으로는 각각의 실시예와 비교예 조성물을 시험관에 0.5 mL씩 분주하고 여기에 25% Na2CO3 용액 0.5 ml를 첨가하여 3분간 정치시켰다. 여기에 2N-Folin-Ciocalteu 페놀 시약 0.25 ml를 첨가하여 혼합한 다음 30℃에서 1시간 동안 정치시킨 후 분광광도계를 사용하여 750 nm에서 흡광도를 측정하였다. 이때 수용성 페놀릭스 함량은 미리 작성해둔 표준품(갈산, Gallic acid) 검량곡선으로부터 함량을 구하고 그 결과는 도 2a에 도시하였다. Specifically, 0.5 mL of each Example and Comparative Example composition was dispensed into test tubes, and 0.5 ml of a 25% Na 2 CO 3 solution was added thereto, and allowed to stand for 3 minutes. To this, 0.25 ml of 2N-Folin-Ciocalteu phenol reagent was added and mixed, and then allowed to stand at 30 ° C. for 1 hour, and absorbance was measured at 750 nm using a spectrophotometer. At this time, the content of the water-soluble phenolics was obtained from a standard calibration curve prepared in advance (Gallic acid), and the results are shown in FIG. 2A.
도 2a에 나타낸 바와 같이, 수용성 페놀릭스 함량은 비교예에 비하여, 실시예 1~4의 에너지 음료 조성물에서 현저히 증진되었다.As shown in Figure 2a, the water-soluble phenolics content was significantly improved in the energy drink compositions of Examples 1 to 4, compared to the comparative example.
<플라보노이드스 함량><Flavonoids content>
각각의 실시예와 비교예 조성물 0.1 ml에 1 N NaOH 0.01 ml를 첨가한 후 디에틸렌글리콜 1.0 ml를 첨가하여 37℃에서 1시간 방치 후 420 nm 흡광도를 측정하였다. 이때 플라보노이드스 함량은 표준품(루틴, rutin) 검량곡선으로부터 함량을 구하였고 루틴에 상응하는 양을 mg/ml로 산출하여 도 2b에 나타내었다. After adding 0.01 ml of 1 N NaOH to 0.1 ml of each Example and Comparative Example composition, 1.0 ml of diethylene glycol was added thereto, and after standing at 37 ° C. for 1 hour, absorbance at 420 nm was measured. At this time, the content of flavonoids was obtained from the standard (routine, rutin) calibration curve, and the amount corresponding to rutin was calculated in mg / ml and is shown in FIG. 2B.
도 2b에 나타낸 바와 같이, 플라보노이드스 함량도, 비교예와 비교했을 시 실시예 1~4의 에너지 음료 조성물은 현저히 증진되었다.As shown in Figure 2b, the flavonoids content, when compared to the comparative example, the energy drink composition of Examples 1-4 was significantly improved.
시험예Test example 4. 항산화 활성 분석 4. Antioxidant activity analysis
항산화 활성은 DPPH 라디칼 소거활성, ABTS 라디칼 소거활성, 하이드록실 라디칼 소거활성과 FRAP 환원력을 측정하여 나타내었다.Antioxidant activity was measured by measuring DPPH radical scavenging activity, ABTS radical scavenging activity, hydroxyl radical scavenging activity and FRAP reducing power.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
각각의 실시예와 비교예의 조성물 0.1 ml에, DPPH 용액(1.5×10-4 M) 0.4 ml를 첨가하여 균일하게 혼합한 30분간 방치한 후 525 nm에서 흡광도를 측정하여 수행하였다. DPPH 라디칼 소거활성의 음성 대조구는 각각의 실시예의 조성물 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3a에 도시하였다. To 0.1 ml of the composition of each Example and Comparative Example, 0.4 ml of DPPH solution (1.5 × 10 −4 M) was added and left to stand for 30 minutes after uniformly mixing, and the absorbance was measured at 525 nm. The negative control of DPPH radical scavenging activity was performed in the same manner using distilled water instead of the composition of each example, and the difference in absorbance was calculated as a percentage (%) by the following equation, and the results are shown in FIG. 3A.
라디칼 소거활성(%) = [1-(음성대조구 흡광도 ÷ 실험구 흡광도)]×100Radical scavenging activity (%) = [1- (absorbance of negative control ÷ absorbance of experimental sphere)] × 100
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
ABTS 라디칼 소거활성은 7 mM ABTS 시약 5 ml과 140 mM K2S2O8 (FW 270.3, Sigma 9392) 5 ml을 섞어 암실에서 16시간 방치시켜 양이온 라디칼을 생성시킨 후, 이를 메탄올로 섞어 732 nm에서 대조구의 흡광도 값이 0.7±0.02가 되도록 조절한 ABTS 용액을 사용하였다. For ABTS radical scavenging activity, 5 ml of 7 mM ABTS reagent and 5 ml of 140 mM K 2 S 2 O 8 (FW 270.3, Sigma 9392) were mixed and left in the dark for 16 hours to generate cationic radicals, followed by mixing with methanol to mix with 732 nm. The ABTS solution adjusted so that the absorbance value of the control was 0.7 ± 0.02 was used.
각각의 실시예와 비교예의 조성물 0.1 ml와 ABTS 용액 0.9 ml를 혼합하여 3분간 반응시키고 732 nm에서 흡광도를 측정하였다. ABTS 라디칼 저해활성 역시 음성 대조구는 각 조성물 대신 증류수로 대체하여 동일한 방법으로 수행, 흡광도의 차이를 상기 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3b에 나타냈다. 0.1 ml of the composition of each Example and Comparative Example and 0.9 ml of ABTS solution were mixed for 3 minutes, and absorbance was measured at 732 nm. The ABTS radical inhibitory activity was also performed in the same way by substituting distilled water for each composition, and the difference in absorbance was calculated as a percentage (%) by the above formula, and the results are shown in FIG. 3B.
<하이드록실 라디칼 소거활성><Hydroxyl radical scavenging activity>
하이드록실(·OH) 라디칼 소거활성은 FeSO4 .7H20-EDTA(10 mM) 2 ml와 2-데옥시리보스(10 mM) 0.2 ml, H2O2(10 mM) 0.2 ml, 각각의 실시예와 비교예의 조성물 1.4 ml를 혼합하고 37℃에서 4시간 반응시켜 이 혼합액에 1% TBA(thiobarbituric acid)와 2.8% TCA(trichloroaceric acid)를 각각 1 ml 첨가하여 100℃에서 20분간 발색시켜 냉각시킨 후 520 nm에서 흡광도를 측정하여 행하였다. 라디칼 소거활성은 시료용액의 첨가구와 무첨가구 사이의 흡광도의 차이를 상기 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3c에 나타내었다. Hydroxy (· OH) radical scavenging activity is FeSO 4 . 2 ml of 7H 2 0-EDTA (10 mM) and 0.2 ml of 2-deoxyribose (10 mM), 0.2 ml of H 2 O 2 (10 mM), 1.4 ml of the composition of each Example and Comparative Example, and mixed at 37 ° C. After reacting for 4 hours, 1 ml of 1% TBA (thiobarbituric acid) and 2.8% trichloroaceric acid (TCA) were added to the mixture, followed by color development at 100 ° C. for 20 minutes, followed by cooling by measuring absorbance at 520 nm. The radical scavenging activity was calculated as the percentage (%) of the difference in absorbance between the addition and non-addition of the sample solution, and the results are shown in FIG. 3C.
<FRAP 환원력 분석><FRAP reducing power analysis>
FRAP(Ferric reducing antioxidant power) 환원력 분석은 화합물의 환원력을 측정하는 방법이다. 더욱 더 상세하게는 Fe3-TPTZ(ferric tripyridyl triazine)가 시료의 환원력에 의하여 푸른색의 Fe2-TPTZ(ferrous tripyridyl triazine)으로 환원될 때 흡광도를 측정하여 항산화 활성을 알아보는 것이다. FRAP (Ferric reducing antioxidant power) is a method of measuring the reducing power of a compound. In more detail, when the Fe3-TPTZ (ferric tripyridyl triazine) is reduced to blue Fe2-TPTZ (ferrous tripyridyl triazine) by the reducing power of the sample, the absorbance is measured to determine the antioxidant activity.
FRAP 환원력 측정에서 반응물질로는 30 mM 아세테이트 완충액(pH 3.6), 40 mM 염산에 녹인 10 mM 2,4,6-트리피리딜-s-트리아진(TPTZ, T1253, C18H12N6, MW312.33) 및 20 mM FeCl3(F7134, MW 162.20, in DW)를 사용하였고, 아세테이트 완충액, TPTZ 용액 및 FeCl3 용액을 10:1:1 (v/v/v)로 혼합하여 37℃에서 15분간 예비반응을 시켜두었다. As a reactant in FRAP reducing power measurement, 30 mM acetate buffer (pH 3.6), 10 mM 2,4,6-tripyridyl-s-triazine dissolved in 40 mM hydrochloric acid (TPTZ, T1253, C18H12N6, MW312.33) and 20 mM FeCl 3 (F7134, MW 162.20, in DW) was used, and the acetate buffer, TPTZ solution and FeCl 3 solution were mixed at 10: 1: 1 (v / v / v) to pre-react at 37 ° C for 15 minutes. Ordered.
상기에서 준비된 각각의 실시예 및 비교예 조성물 0.05 ml와 FRAP 시약 0.95 ml를 시험관에 분주한 후, 약 15분간 반응시키고 593 nm에서 흡광도를 측정하여 그 결과를 도 3d에 나타냈다.After dispensing 0.05 ml of each Example and Comparative Example composition prepared above and 0.95 ml of FRAP reagent into a test tube, reacting for about 15 minutes and measuring absorbance at 593 nm, the results are shown in FIG. 3D.
도 3a ~ 도 3d에 도시된 바와 같이, 비교예의 음료 조성물와 비교하였을 때, 본 발명에 따른 실시예 1~4의 에너지 음료 조성물은 DPPH 라디칼 소거활성이 평균 37.31%로 현저히 증진되었고, ABTS 라디칼 소거활성, 히드록실 라디칼 소거활성, FRAP 환원력도 현저히 증진되었음을 확인할 수 있다. 특히 실시예 2의 에너지 음료 조성물은 ABTS 라디칼 소거활성은 60%, 히드록실 라디칼 소거활성은 53%, FRAP 환원력은 1.89로 항산화 활성이 매우 우수하였다. 3A to 3D, when compared with the beverage composition of the comparative example, the energy beverage compositions of Examples 1 to 4 according to the present invention had a significantly enhanced DPPH radical scavenging activity on average of 37.31%, and ABTS radical scavenging activity , It can be seen that hydroxyl radical scavenging activity and FRAP reducing power are also significantly improved. In particular, the energy drink composition of Example 2 was ABTS radical scavenging activity was 60%, hydroxyl radical scavenging activity was 53%, FRAP reducing power was 1.89, which was very excellent in antioxidant activity.
시험예Test example 5. 5. 항당뇨Anti-diabetes 활성 분석 Active analysis
상기에서 제조된 실시예들과 비교예의 음료 조성물의 항당뇨 활성은 효소(α-glucosidase)를 기반으로 한 모델을 사용하여 수행하였다.The antidiabetic activity of the beverage compositions of Examples and Comparative Examples prepared above was performed using a model based on enzymes (α-glucosidase).
상기에서 준비된 각각의 실시예 및 비교예 조성물 1.0 ml, 효소용액(α-glucosidase, 1.0 unit/ml) 1.0 ml, 그리고 인산나트륨 완충용액(pH 6.8, 200 mM) 1.0 ml를 시험관에 분주하고 37℃의 수욕상에서 15분간 예비반응을 수행하였다. 예비반응 종료 후 인산나트륨 완충용액에 용해된 파라-니트롤페닐 글리코젠(5 mM) 0.5 ml를 가하여 37℃의 수욕상에서 최종 효소반응을 수행하였다. 효소반응 종료 후 이 반응물에 탄산나트륨(100 mM) 0.75 ml를 첨가하여 반응을 종결시킨 뒤 420 nm에서 흡광도를 측정하였고 이때 음성대조구는 각 조성물 대신 증류수로 대체하여 상기 라디칼 소거활성과 동일한 계산식에 대입하여 최종 %로 저해활성을 산출하여, 그 결과를 도 4에 나타냈다.1.0 ml of each Example and Comparative Example composition prepared above, 1.0 ml of enzyme solution (α-glucosidase, 1.0 unit / ml), and 1.0 ml of sodium phosphate buffer solution (pH 6.8, 200 mM) were dispensed into a test tube and 37 ℃ Preliminary reaction was performed in the water bath for 15 minutes. After completion of the pre-reaction, 0.5 ml of para-nitrophenyl glycogen (5 mM) dissolved in a sodium phosphate buffer solution was added to perform a final enzymatic reaction in a water bath at 37 ° C. After completion of the enzymatic reaction, 0.75 ml of sodium carbonate (100 mM) was added to the reaction product to terminate the reaction, and absorbance was measured at 420 nm. At this time, the negative control was replaced with distilled water instead of each composition, and substituted into the same formula as the radical scavenging activity. The inhibitory activity was calculated by the final%, and the results are shown in FIG. 4.
도 4에 도시된 바와 같이, 실시예 1~4의 에너지 음료 조성물은, 비교예(3%)에 비하여, 약 2~4배 (7~13.44%) 증진된 α-글루코시다제 저해활성은 나타냈다. 이와 같은 결과로부터 본 발명의 에너지 음료 조성물은 항당뇨 활성이 현저히 강화됨을 알 수 있다. As shown in FIG. 4, the energy drink compositions of Examples 1 to 4 exhibited about 2 to 4 fold (7 to 13.44%) enhanced α-glucosidase inhibitory activity compared to Comparative Example (3%). . From these results, it can be seen that the energy drink composition of the present invention has significantly enhanced anti-diabetic activity.
Claims (5)
상기 활성산양삼 추출액은 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 활성산양삼을 제조한 후, 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 120℃에서 8∼10시간 동안 추출한 후 여과하여 4 브릭스 농도로 제조된 것이고,
상기 음료 조성물은 1.03~8.22 mg/100ml로 증진된 가바 함량, 16.85~25.47 ㎍/ml로 증진된 에피카테킨 함량 및 40.16~43.86 ㎍/ml로 증진된 클로로제닉산을 함유하고, 40~60%로 증진된 ABTS 라디칼 소거활성을 갖고, 7~13.44%로 증진된 α-글루코시다제 저해활성을 갖는 것을 특징으로 하는 에너지 음료 조성물.
Yeoju extract 45 ~ 55% by weight, active wild ginseng extract 1 ~ 5% by weight, Omija sugar extract 4 ~ 12% by weight, green tea extract 1 ~ 5% by weight, guarana extract 0.8 ~ 1.4% by weight, taurine 0.2 ~ 2.0% by weight and the rest An energy drink composition comprising water,
The active ginseng extract is prepared by evaporating the wild ginseng at 100 ° C for 30 to 60 minutes, and then evaporating the boiled wild ginseng at 70 to 90 ° C for 2 to 4 days at high temperature three times to prepare the active ginseng, and then at 2 to 50 to 55 ° C. After drying for 3 days, powdered to 100 mesh or less, 10-20 times (v / w) hydrolyzed, extracted at 120 ° C. for 8-10 hours, filtered and prepared at a concentration of 4 Brix,
The beverage composition contains a gaba content enhanced to 1.03 to 8.22 mg / 100 ml, an epicatechin content enhanced to 16.85 to 25.47 μg / ml, and a chlorogenic acid enhanced to 40.16 to 43.86 μg / ml, enhanced to 40-60% Energy drink composition characterized by having an ABTS radical scavenging activity and an α-glucosidase inhibitory activity enhanced to 7-13.44%.
ⅰ) 여주분말에 10~20배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 1 브릭스 농도의 여주 추출액을 제조하는 단계;
ⅱ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복하여 활성산양삼을 제조한 후, 50∼55℃에서 2~3일 건조시킨 후 100 메쉬 이하로 분말화하고, 10∼20배(v/w) 가수하여 120℃에서 8∼10시간 동안 추출한 후 여과하여 4 브릭스 농도의 활성산양삼 추출액을 제조하는 단계;
ⅲ) 오미자와 설탕을 1 : 1 중량비로 혼합하여 50~60일 동안 당절임 후 여과하여 60 브릭스 농도의 오미자당 추출액을 제조하는 단계;
ⅳ) 녹차분말을 10~20 배의 물을 가수하여 120℃에서 8시간 추출하여 여과하여 2 브릭스 농도의 녹차 추출액을 제조하는 단계;
ⅴ) 여주 추출액 45~55 중량%, 활성산양삼 추출액 1~5 중량%, 오미자당 추출액 4~12 중량%, 녹차 추출액 1~5 중량%, 과라나 추출물 0.8~1.4 중량%, 타우린 0.2~2.0 중량% 및 나머지 물을 혼합하는 단계를 포함하여 이루어지는 에너지 음료 조성물의 제조방법.A method for producing an energy drink composition according to claim 1, wherein the method
Iv) preparing a Yeoju extract having a concentration of 1 Brix by adding 10-20 times water to the Yeoju powder and extracting it at 120 ° C for 8 hours;
Ii) Steamed wild ginseng at 100 ℃ for 30 ~ 60 minutes, and steamed wild ginseng was repeated three times for 2-4 days at 70-90 ℃ to prepare active ginseng, and then dried at 50-55 ℃ for 2-3 days After making the powder to 100 mesh or less, and 10 to 20 times (v / w) hydrolyzed to extract for 8 to 10 hours at 120 ℃ filtered to prepare an active wild ginseng extract of 4 Brix concentration;
Iv) preparing Omija sugar extract of 60 Brix concentration by mixing Omizawa sugar in a 1: 1 weight ratio, pickling and filtering for 50-60 days;
Iv) preparing a green tea extract having a concentration of 2 Brix by filtering the green tea powder with water 10 to 20 times and extracting it at 120 ° C. for 8 hours;
Ⅴ) Yeoju extract 45 ~ 55% by weight, Active wild ginseng extract 1 ~ 5% by weight, Omija sugar extract 4 ~ 12% by weight, Green tea extract 1 ~ 5% by weight, Guarana extract 0.8 ~ 1.4% by weight, Taurine 0.2 ~ 2.0% by weight And mixing the rest of the water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180142305A KR102105111B1 (en) | 2018-11-19 | 2018-11-19 | Energy drink composition containing increased biological active materials and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180142305A KR102105111B1 (en) | 2018-11-19 | 2018-11-19 | Energy drink composition containing increased biological active materials and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102105111B1 true KR102105111B1 (en) | 2020-04-27 |
Family
ID=70467904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180142305A KR102105111B1 (en) | 2018-11-19 | 2018-11-19 | Energy drink composition containing increased biological active materials and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102105111B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114103592A (en) * | 2021-11-22 | 2022-03-01 | 泉州装备制造研究所 | Movable container type heat pump drying system, transport vehicle and drying method |
WO2022040720A1 (en) * | 2020-08-28 | 2022-03-03 | Red Kangaroo Beverages Pty Ltd | Caffeinated botanical infusion beverage and method of making same |
KR20230087021A (en) | 2021-12-09 | 2023-06-16 | 광동제약 주식회사 | Composition for fatigue recovery comprising the Cervus Parvum Cornu extract as active ingredients |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090030803A (en) * | 2007-09-21 | 2009-03-25 | 천지영농조합법인 | The beverage of ginseng |
KR20130009506A (en) * | 2011-07-15 | 2013-01-23 | 김종배 | Cucurbitane and bitter gourd extracts for enhancing exercise performance and suppressing fatigue, and a composition containing the same |
KR20130066963A (en) * | 2011-12-13 | 2013-06-21 | 함양영농조합법인 | Manufacturing method for the beverage of momordica charantia having high antioxidant activity |
KR101691334B1 (en) * | 2016-08-30 | 2016-12-29 | 최승 | Method for producing red ginseng extract with enhanced ginsenoside content, red ginseng extract and red ginseng processed-food thereof |
-
2018
- 2018-11-19 KR KR1020180142305A patent/KR102105111B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090030803A (en) * | 2007-09-21 | 2009-03-25 | 천지영농조합법인 | The beverage of ginseng |
KR20130009506A (en) * | 2011-07-15 | 2013-01-23 | 김종배 | Cucurbitane and bitter gourd extracts for enhancing exercise performance and suppressing fatigue, and a composition containing the same |
KR20130066963A (en) * | 2011-12-13 | 2013-06-21 | 함양영농조합법인 | Manufacturing method for the beverage of momordica charantia having high antioxidant activity |
KR101691334B1 (en) * | 2016-08-30 | 2016-12-29 | 최승 | Method for producing red ginseng extract with enhanced ginsenoside content, red ginseng extract and red ginseng processed-food thereof |
Non-Patent Citations (1)
Title |
---|
"항산화 에너지멀티비타민 - 포도맛", 네이버 블로그, https://shine8252.blog.me/ 221261795632 (2018.04.26.)* * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022040720A1 (en) * | 2020-08-28 | 2022-03-03 | Red Kangaroo Beverages Pty Ltd | Caffeinated botanical infusion beverage and method of making same |
CN114103592A (en) * | 2021-11-22 | 2022-03-01 | 泉州装备制造研究所 | Movable container type heat pump drying system, transport vehicle and drying method |
CN114103592B (en) * | 2021-11-22 | 2023-11-21 | 泉州装备制造研究所 | Movable container type heat pump drying system, transport vehicle and drying method |
KR20230087021A (en) | 2021-12-09 | 2023-06-16 | 광동제약 주식회사 | Composition for fatigue recovery comprising the Cervus Parvum Cornu extract as active ingredients |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080038367A1 (en) | Nutritional supplement compositions and methods of preparing | |
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
KR102105111B1 (en) | Energy drink composition containing increased biological active materials and preparation method thereof | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
EP2003988B1 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea | |
WO2006090935A1 (en) | Acerola fruit-derived pectin and use thereof | |
KR20140103622A (en) | The method for manufacturing functional tea product made from onion skin, and the product made by the method | |
US9173916B2 (en) | Method of preparing a muscadine pomace extract | |
Wolska et al. | Influence of temperature and brewing time of nettle (Urtica dioica L.) infusions on vitamin C content | |
Gawron-Gzella et al. | Antioxidant activity of teas obtained from leaves of Camellia sinensis (L.) Kuntze in course of various production processes available on Polish market | |
KR102007576B1 (en) | Beverage composition of Aronia melanocarpa containing active ginsenosides and preparation method thereof | |
Oboh et al. | Antioxidant properties and inhibitory effect of ethanolic extract of struchium sparganophora (ewuro odo) leaf on α-amylase and α–glucosidase activities | |
KR20200042325A (en) | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR20190006702A (en) | Method for manufacturing the functional beverage containing Chaenomeles sinensis Koehne, Mentha arvensis var and Cornus officinalis sieb and the functional beverage prepared therefrom | |
Marnewick | Antioxidant properties of Rooibos (Aspalathus linearis)–in vitro and in vivo evidence | |
KR101930026B1 (en) | manufacturing method of black garlic beverage having effect to improve liver function | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
KR20110037020A (en) | The anti-diabetes composition containing silkworm culturing product and medicinal herbs | |
KR20210050103A (en) | Immune enhancing liquid composition having increased ginsenosides Rb1, Rg1 and Rg3 and preparation method thereof | |
KR102661369B1 (en) | A functional food composition for preventing and relieving hangover enriched with steamed and lyophilized mature silkworm | |
CA2904636C (en) | Method of preparing a muscadine pomace extract | |
KR20130060436A (en) | Food additives comprising the extract of processed panax ginseng for hepato-protective activity | |
KR102588372B1 (en) | Composition comprising natural complex extract for prenenting, improving or treating gastritis and peptic ulcer | |
KR102341886B1 (en) | A natural tea removing the effect of hangover contained the extract material in acer tegmentosum and Alnus japonica | |
KR102044607B1 (en) | Tea of whole mountain-cultivated ginseng having increased active ginsenoside, chlorgenic acid and quercetin, and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant |